http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-040398-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 |
| filingDate | 2003-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-040398-A1 |
| titleOfInvention | INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT |
| abstract | A compound of thienopyridine or thienopyrimidine represented by the formula (1), where X is -CH- or -N-; Y is -NH-, -O-, -S-, or -CH2-; R1 is indole substituted in the N position with -C (O) NR6R7 or -C (O) NHCH2C ::: CH and optionally R1 is also substituted with 1 to 4 R5 substituents; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, -C (O) R8, -C (O) OR8, -OC (O) R8, -OC (O) OR8, -NR6C (O ) R7, -C (O) NR6R7, -NR6R7, -OR9, -SO2NR6R7, C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkylamino, - (CH2) jO (CH2) qNR6R7, - (CH2) tO ( CH2) qOR9, - (CH2) tOR9, -S (O) j (C1-6 alkyl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - C (O) (CH2) t (C6-10 aryl), - (CH2) tO (CH2) j (C6-10 aryl), - (CH2) tO (CH2) q (5-10 membered heterocyclyl), - C (O) (CH2) t (5-10 membered heterocyclyl), - (CH2) jNR7 (CH2) qNR6R7, - (CH2) jNR7CH2C (O) NR6R7, - (CH2) jNR7 (CH2) qNR9C (O) R8 , - (CH2) jNR7 (CH2) tO (CH2) qOR9, - (CH2) jNR7 (CH2) qS (O) j (C1-6 alkyl), - (CH2) jNR7 (CH2) tR6, -SO2 (CH2) t (C6-10 aryl), and -SO2 (CH2) t (5-10 membered heterocyclyl), where j is an integer from 0 to 2, t is an integer from 0 to 6, q is an integer from 2 to 6, the residues - (CH2) q- and - (CH2) t- of said R5 groups optionally include a double or triple carbon-carbon bond, where t it is an integer between 2 and 6, and the alkyl, aryl and heterocyclyl moieties of said R5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -OH, -C ( O) R8, -C (O) OR8, -OC (O) R8, -OC (O) OR8, -NR6C (O) R7, -C (O) NR6R7, - (CH2) tNR6R7, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, where t is an integer from 0 to 6 and q is an integer from 2 to 6; each of R6 and R7 is independently selected from H, OH, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, - (CH2) tCN (CH2) tOR9, - (CH2) tCN (CH2) tR9 and - (CH2) tOR9, where t is an integer from 0 to 6 and q is a number integer from 2 to 6, and the alkyl, aryl and heterocyclyl moieties of said R6 and R7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, -C (O) R8, -C (O) OR8, -CO (O) R8, -OC (O) OR8, -NR9C (O) R10, -C (O) NR9R10, -NR9R10, C1-6 alkyl, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, where t is an integer from 0 to 6 and q is an integer from 2 to 6, where when both of R6 and R7 are attached to the same nitrogen, then both of R6 and R7 are not attached to nitrogen directly through an oxygen; each R8 is independently selected from H, C1-10 alkyl, C3-10 cycloalkyl, - (CH2) t (C6-10 aryl), and - (CH2) t (5-10 membered heterocyclyl), where t is a number integer from 0 to 6; each of R9 and R10 is independently selected from H, -OR6, C1-6 alkyl, and C3-10 cycloalkyl; and R11 is H, C1-6 alkyl, C3-10 cycloalkyl, -C (O) NR12R13, -C (O) (C6-10 aryl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tNR12R13, -SO2NR12R13 and -CO2R12, where t is an integer from 0 to 6, wherein said C1-6 alkyl moieties, -C (O) (C6 aryl- 10), - (CH2) t (C6-10 aryl), and - (CH2) t (5-10 membered heterocyclyl) of said R11 groups are unsubstituted or substituted with one or more R5 groups; each of R12 and R13 is independently selected from H, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) t (C3-10 cycloalkyl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, q is an integer from 2 to 6, and the alkyl, aryl and heterocyclyl moieties of said R12 groups and R13 are unsubstituted or substituted with one or more substituents independently selected from R5, or R2 and R13 are taken together with the nitrogen to which they are attached to form a C5-9 azabicyclic ring, aziridinyl, azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl , thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl, wherein said C5-9 azabicyclic rings, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl are unsubstituted or substituted by one or more of the substituted R 2 R12 and R13 are not directly bound to nitrogen through an oxygen; or prodrugs thereof, pharmaceutically acceptable salts or solvates of said compound and said prodrugs. A compound represented by the formula (2) and pharmaceutically acceptable salts thereof, in which: Z1 is halo, -CO2H, -CONH2, -CSNH2 and Z2 is -OR1; or Z1 is R11 and Z2 is halo; or each of Z1 and Z2 is independently halo; R1 is H, C1-6 alkyl, C3-10 cycloalkyl, -C (O) (C1-6 alkyl), C6-10 aryl or a 5-13 membered heterocyclyl; wherein said C6-10 aryl and 5 to 13 membered heterocyclyl groups are unsubstituted or substituted with 1 to 5 R5 substituents; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, -C (O) R8, -C (O) OR8, -OC (O) R8, -OC (O) OR8, -NR6C (O ) R7, -C (O) NR6R7, -NR6R7, -OR9, -SO2NR6R7, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) jO (CH2) qNR6R7, - (CH2) tO (CH2) qOR9, - (CH2) tOR9, -S (O) j (C1-6 alkyl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), -C (O) ( CH2) t (C6-10 aryl), - (CH2) tO (CH2) j (C6-10 aryl), - (CH2) tO (CH2) q (5-10 membered heterocyclyl), -C (O) ( CH2) t (5-10 membered heterocyclyl), - (CH2) jNR7 (CH2) qNR6R7, - (CH2) jNR7CH2C (O) NR6R7, - (CH2) jNR7 (CH2) qNR9C (O) R8, - (CH2) jNR7 (CH2) tO (CH2) qOR9, - (CH2) jNR7 (CH2) qS (O) j (C1-6 alkyl), - (CH2) jNR7 (CH2) tR6, -SO2 (CH2) t (C6 aryl- 10), and -SO2 (CH2) t (5-10 membered heterocyclyl), where j is an integer from 0 to 2, t is an integer from 0 to 6, q is an integer from 2 to 6, residues - (CH2) q- and - (CH2) t- of said R5 groups optionally include a double or triple carbon-carbon bond, where t is an inte number ro between 2 and 6, and the alkyl, aryl and heterocyclyl moieties of said R5 groups are unsubstituted or substituted with one or more substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -OH, -C (O) R8 , -C (O) OR8, -OC (O) R8, -OC (O) OR8, -NR6C (O) R7, -C (O) NR6R7, - (CH2) tNR6R7, C1-6 alkyl, C3 cycloalkyl 10, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, where t is a number integer from 0 to 6 and q is an integer from 2 to 6; each of R6 and R7 is independently selected from H, OH, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, - (CH2) tCN (CH2) tOR9, - (CH2) tCN (CH2) tR9 and - (CH2) tOR9, where t is an integer from 0 to 6 and q is a number integer from 2 to 6, and the alkyl, aryl and heterocyclyl moieties of said R6 and R7 groups are unsubstituted or substituted with one or more substituents independently selected from hydroxy, halo, cyano, nitro, trifluoromethyl, azido, -C (O) R8, -C (O) OR8, -CO (O) R8, -OC (O) OR8, -NR9C (O) R10, -C (O) NR9R10, -NR9R10, C1-6 alkyl, - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, where t is an integer from 0 to 6 and q is an integer from 2 to 6, where when both of R6 and R7 are attached to the same nitrogen, then both of R6 and R7 are not attached to nitrogen directly through an oxygen; each R8 is independently selected from H, C1-10 alkyl, C3-10 cycloalkyl, - (CH2) t (C6-10 aryl), and - (CH2) t (5-10 membered heterocyclyl), where t is a number integer from 0 to 6; each of R9 and R10 is independently selected from H, -OR6, C1-6 alkyl, and C3-10 cycloalkyl; and R11 is H, C1-6 alkyl, C3-10 cycloalkyl, -C (O) NR12R13, -C (O) (C6-10 aryl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tNR12R13, -SO2NR12R13 and -CO2R12, where t is an integer from 0 to 6, wherein said R11 C1-6 alkyl moieties, -C (O) (C6 aryl -10), - (CH2) t (C6-10 aryl), and - (CH2) t (5-10 membered heterocyclyl) of said R11 groups are unsubstituted or substituted with one or more R5 groups; each of R12 and R13 is independently selected from H, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) t (C3-10 cycloalkyl), - (CH2) t (C6-10 aryl), - (CH2) t (5-10 membered heterocyclyl), - (CH2) tO (CH2) qOR9, and - (CH2) tOR9, q is an integer from 2 to 6, and the alkyl, aryl and heterocyclyl moieties of said R12 groups and R13 are unsubstituted or substituted with one or more substituents independently selected from R5, or R2 and R13 are taken together with the nitrogen to which they are attached to form a C5-9 azabicyclic ring, aziridinyl, azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, morpholinyl , thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl, wherein said C5-9 azabicyclic rings, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, isoquinolinyl, or dihydroisoquinolinyl are unsubstituted or substituted by one or more of the substituted R 2 R12 and R13 are not directly bound to nitrogen through an oxygen; or prodrugs thereof, pharmaceutically acceptable salts or solvates of said compound and said prodrugs. A compound represented by the formula (3) where Y is -NH-, -O-; R 14 is C 1-6 alkyl, C 3-10 cycloalkyl, or methylureido; R15, R16 and R17 are independently an H group or C1-6 alkyl; and R11 is a heterocyclic or heteroaryl group unsubstituted or substituted with one or more halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, -C (O) R8, -C (O) OR8, -OC (O) R8, - OC (O) OR8, -NR6C (O) R7, -C (O) NR6R7, -NR6R7, -OR9, -SO2NR6R7, C1-6 alkyl, C3-10 cycloalkyl, - (CH2) jO (CH2) qNR6R7, - (CH2) tO (CH2) qOR9, - (CH2) tOR9, -S (O) j (C1-6 alkyl), - (CH2) t (C6-10 aryl), - (CH2) t (heterocyclyl from 5 to 10 members), -C (O) (CH2) t (C6-10 aryl), - (C |
| priorityDate | 2002-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.